SEEK ID: https://seek.lisym.org/assays/8
Experimental assay
Projects: LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP)
Investigation: Julia/Yan
Study: CCl4 Treatment in mice
Assay position:
Assay type: Proteomics
Technology type: FACS
Organisms: Mus musculus
Export PNG
Views: 2773
Created: 21st Nov 2017 at 15:02
Last updated: 13th Dec 2021 at 09:46
This item has not yet been tagged.
Related items
Projects: LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP), LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF), LiSyM network, LiSyM PALs, LiSyM-Krebs Partnering, C-TIP-HCC network
Institutions: Molecular Hepatology - Dept of Medicine II - Medical Faculty Mannheim - Heidelberg University
Liver Systems Medicine : striving to develop non-invasive methods for diagnosing and treating NAFLD by combining mathematical modeling and biological research. LiSyM, is a multidisciplinary research network, in which molecular and cell biologists, clinical researchers, pharmacologists and experts in mathematical modeling examine the liver in its entirety. LiSyM research focuses on the metabolic liver disease non-alcoholic fatty liver disease (NAFLD), which includes non-alcoholic steatohepatitis ...
Projects: LiSyM Core Infrastructure and Management (LiSyM-PD), LiSyM Pillar I: Early Metabolic Injury (LiSyM-EMI), LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP), LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF), LiSyM Pillar IV: Liver Function Diagnostics (LiSyM-LiFuDi), Model Guided Pharmacotherapy In Chronic Liver Disease (LiSyM-MGP), Molecular Steatosis - Imaging & Modeling (LiSyM-MSIM), The Hedgehog Signalling Pathway (LiSyM-JGMMS), Multi-Scale Models for Personalized Liver Function Tests (LiSyM-MM-PLF), LiSyM PALs, Project Management PTJ, LiSyM network, LiSyM Scientific Leadership Team (LiSyM-LT)
Web page: https://www.lisym.org/
In one in five people with NAFLD, the functioning liver cells, the hepatocytes, are replaced by connective tissue. Eventually this fibrosis becomes irreversible. In this state the liver is like a ‘scar that never heals’. Through it, the liver loses many of its vital functions. LiSyM-Pillar II wants to know more about which factors promote fibrosis and the conditions under which fibrosis becomes irreversible How can fibrosis be diagnosed as early as possible? Researchers in the pillar are also ...
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org/our-work/pillar-research
Start date: 1st Jan 2016
Organisms: Mus musculus, Rattus rattus, Rattus norvegicus, Homo sapiens
Pillar II dooley
Snapshots: No snapshots
Snapshots: No snapshots
Supplmentary Materials, Methods, Figures and Tables
List of used antibodies
Publications in which periportal fibrosis has been reported after repeated doses of CCl4.
Materials and Methods
CYP2E1 activity in HepG2-E47 was measured. TAM inhibits (not significantly) the CYP2E1 activity compared to alcohol and DMSO-treated cells. C34 cell line was used as a negative control. Bars represent the means±SD of 3 biological replica. Student’s t test (paired t test) was used to check the statistical differences upon TAM incubation (JPG 1530 KB)
This SOP - Standard Operating Procedure for Sample Collection and Preservation of Blood and Endometrial Tissue were developed at NIH University of California San Francisco Human Endometrial Tissue and DNA Bank by Elizabeth Sheldonand, Ramsey A McIntire
Creators: Olga Krebs, Martin Golebiewski, Elizabeth Sheldonand, Ramsey A McIntire
Submitter: Olga Krebs
Investigations: Julia/Yan and 1 hidden item
Studies: CCl4 Treatment in mice and 1 hidden item
Assays: Metabolic CCl4 and 1 hidden item